Bryan Wahl Sells 3,341 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the transaction, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 20th, Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $50.11, for a total value of $154,539.24.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $49.97 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.92 billion, a PE ratio of -13.12 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The firm’s 50-day simple moving average is $48.48 and its two-hundred day simple moving average is $45.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on TARS. HC Wainwright reissued a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim reissued a “buy” rating and issued a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $63.67.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in TARS. Paradigm Biocapital Advisors LP lifted its holdings in Tarsus Pharmaceuticals by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company’s stock worth $140,191,000 after purchasing an additional 91,451 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after buying an additional 321,552 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock worth $117,117,000 after buying an additional 17,839 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $105,714,000. Finally, Lord Abbett & CO. LLC grew its stake in Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after acquiring an additional 685,111 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.